Data as of Dec 17
| -0.28 / -0.20%|
Shire Plc is a biopharmaceutical company that focuses on meeting the needs of physicians. It focuses its business on attention deficit hyperactivity disorder, human genetic therapies and gastrointestinal diseases, as well as opportunities in other therapeutic areas. It operates under three segments which include Specialty Pharma, Human Genetic Therapies and Regenerative Medicine. The Specialty Pharmaceuticals segment focuses on small-molecule medications, including Vyvanse for the treatment of attention deficit hyperactivity disorder in children aged 6 to 17, FOSRENOL for the treatment of chronic kidney disease in pre-dialysis patients, XAGRID for the treatment of essential thrombocythaemia, JUVISTA for the improvement of scar appearance, LIALDA/MEZAVANT for the treatment of diverticulitis and RESOLOR for the treatment of chronic constipation in males. The Human Genetic Therapies segment offers products, including FIRAZYR for the treatment of acute hereditary angioedema, REPLAGAL for fabry disease and HGT-2310 for the treatment of Hunter syndrome with central nervous system symptoms, idursulfase-intrathecal delivery. The Regenerative Medicine segment focuses on Dermagraft, a bioengineered skin substitute that assists in restoring damaged tissue and supports the body's natural healing process. The company was founded in 1986 and is headquartered in Dublin, Ireland.
|Flemming Ørnskov||Chief Executive Officer & Director|
|Graham C. Hetherington||CFO, Director, CAO & Investor Relations Contact|
|Mario Saltarelli||Senior VP-Clinical Development & Medical Affairs|
|Mark J. Enyedy||Senior VP & Head-Internal Medicine Business|
|Sheila E. Stranks||Vice President & Deputy Compliance Officer|